Human HLA-specific T-cell clones with stable expression of a suicide gene: A possible tool to drive and control a graft-versus-host-graft-versus-leukemia reaction?

Blood

Volumn 88, Issue 3, 1996, Pages 1098-1103

  Gallot, Géraldine ^b   Hallet, Marie Martine ^b   Gaschet, Joëlle ^b   Moreau, Jean François ^b   Vivien, Régine ^b   Bonneville, Marc ^b   Milpied, Noël ^b   Vié, Henri ^a  

^a INSERM   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GANCICLOVIR; HLA ANTIGEN; THYMIDINE KINASE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CELL CLONE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENETIC TRANSDUCTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HLA SYSTEM; HUMAN; HUMAN CELL; LEUKEMIA; MOLECULAR CLONING; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VIRUS GENE;

EID: 0029744916     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.3.1098.1098     Document Type: Article

References (20)

1. Apperley JF, Mauro FR, Goldman JM, Gregory W, Arthur CK, Hawks J, Arcese W, Papa G, Mandelli F, Wardle D, Gravett P, Franklin IM, Bandini G, Ricci P, Tura S, Iacone A, Torlontano G, Hiet W, Champlin R, Gale RP: Bone marrow transplantation for chronic myelogenous leukemia in first chronic phase: Importance of a graft-versus-leukemia effect. Br J Haematol 69:239, 1988
2. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, The Seattle Marrow Transplant Team: Antileukemic effect of chronic graft-versus-host disease. Contribution for improved survival after allogeneic marrow transplantation. N Engl J Med 304:1529, 1981
3. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-versus-leukemia reaction after bone marrow transplantation. Blood 75:555, 1990
4. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Veronck L, Niederwieser D, van Rhee F, Mitermueller J, de Witte T, Holler E, Ansari H, for the European Group for Blood and Marrow Transplantation: Graftversus-leukemia effect of donor lymphocyte transfusion in marrow grafted recipients. Blood 86:2041, 1995
5. Tiberghien P, Reynolds CW, Keller J, Spence S, Deschaseaux M, Certoux JM, Contassot E, Murphy WJ, Lyons R, Chiang Y, Herve P, Longo DL, Ruscetti FW: Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: An approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 84:1333, 1994
6. Bonneville M, Moreau JF, Blokland E, Pool J, Moisan JP, Goulmy E, Soulillou JP: T lymphocyte cloning from rejected human kidney allograft. Recognition repertoire of alloreactive T cell clones. J Immunol 141:4187, 1988
7. Gaschet J, Mahe B, Milpied N, Devilder MC, Dreno B, Bignon JD, Davodeau F, Hallet MM, Bonneville M, Vie H: Specificity of T cells invading the skin during acute graft versus host disease after semi-allogeneic bone marrow transplantation. J Clin Invest 91:12, 1993
8. Vie H, Chevalier S, Garand R, Moisan JP, Praloran V, Devilder MC, Moreau JF, Soulillou JP: Clonal expansion of lymphocytes bearing the gamma-delta receptor in a patient with a large granular lymphocyte disorder. Blood 74:285, 1989
9. Moisan JP, Bonneville M, Bouyge I, Moreau JF, Soulillou JP, Lefranc MP: Characterization of T-cell receptor (TCR) gamma gene rearrangement in alloreactive T cell clones. Human Immunol 24:95, 1989
10. Blaese RM, Mullen CA, Ramsey WJ: Strategies for gene therapy. Path Biol 8:672, 1993
11. Petersdorf EF, Smith AG, Mickelson EM, Longton GM, Anasetti C, Choo SY, Martin PJ, Hansen A: The role of HLA-DPB1 disparity in the development of acute graft-versus-host disease following unrelated donor marrow tranplantation. Blood 81:1923, 1993
12. Gaschet J, Trevino MA, Cherel M, Vivien R, Garcia-Sahuquillo A, Hallet MM, Boneeville M, Bragado R, Milpied N, Vié H: HLA-target antigen and TCR diversity of activated T cells invading the skin during acute graft-vs-host disease. Blood 87:2345, 1996
13. Blaese RM: Lymphocytes for gene therapy. Human Gene Transf 219:137, 1991
14. Blaese RM, Kenneth WC, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greeblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WF: T lymphocyte-directed gene therapy for ADA-SCID: Initial results after 4 years. Science 270:475, 1995
15. Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, Panina P, Mazzolari E, Maggioni D, Rossi C, Servida P, Ugazio AG, Mavilio F: Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science 270:470, 1995
16. Rooney CM, Smith CA, Ng CYC, Loftin S, Li C, Krance RA, Brenner MK, Heslop H: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9, 1995
17. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Ridell SR: Reconstitution of cellular immunity against CMV in recipients of allogeneic bone marrow transplantation by adoptive transfer of T cell clones from the donor. N Engl J Med 333:1038, 1995
18. Burrows SR, Khanna R, Burrows JM, Moss DJ: An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus epitope: Implications for graft-versus-host disease. J Exp Med 179:1155, 1994
19. Ridell SR, Elliot M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, Lupton SD, Overell RW, Reynolds TC, Corey L, Greenberg PD: T-cell mediated rejection of gene modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Med 2:216, 1996
20. Palmer TD, Rosman GJ, Osborne WR, Miller AD: Genetically modified fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci USA 88:1330, 1991